NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Com...








    



            







    
        
            February 05, 2026 08:00 ET
        

        
             | Source:
            

                LB Pharmaceuticals Inc
            
                

        
    

    

    

    





        
NEW YORK, Feb.  05, 2026  (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced that it has entered into a securities purchase agreement to sell 3,306,571 shares of its common stock and pre-funded warrants to purchase up to 1,417,107 shares of its common stock to a select group of institutional investors in a private placement. The purchase price of each share of common stock is $21.17. The purchase price of each pre-funded warrant is $21.1699, which represents the per share purchase price for the common stock less the $0.0001 per share exercise price for such pre-funded warrant. LB Pharmaceuticals anticipates the gross proceeds from the private placement to be approximately $100.0 million, before deducting any transaction-related expenses. The private placement is expected to close on or about February 6, 2026, subject to the satisfaction of customary closing conditions.  The financing includes participation from new and existing institutional investors, including Balyasny Asset Management L.P., Caligan Partners, Commodore Capital, Deep Track Capital, Nantahala Capital, Pivotal bioVenture Partners, Spruce Street Capital, TCGX, Trails Edge Capital Partners, and other investors.  Leerink Partners, Piper Sandler and Stifel acted as placement agents for the private placement.  LB Pharmaceuticals intends to use the net proceeds from the private placement to fund a Phase 2 trial for LB-102 as an adjunctive treatment for major depressive disorder, and for working capital and general corporate purposes.  The offer and sale of the securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Concurrently with entering into the securities purchase agreement, LB Pharmaceuticals and the investors entered into a registration rights agreement pursuant to which LB Pharmaceuticals has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement, including the shares of common stock underlying the pre-funded warrants.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.  About LB Pharmaceuticals  LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.  Forward-Looking Statements  Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning expected proceeds from the private placement, expected use of proceeds, and expected closing of the private placement. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the late stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.  Media & Investor Contact:Ellen Roseerose@lbpharma.us  
            

LBRX

LB Pharmaceuticals Announces $100.0 Million Private Placement

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Com...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>LB Pharmaceuticals (LBRX) plans to raise approximately $100 million through a private placement of shares to fund a Phase 2 trial for its lead candidate, LB-102. The anticipated proceeds may enhance the company&#039;s position in the neuropsychiatric market, leading to potential stock appreciation following the closure of the placement.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>LBRX announces the sale of 3.3 million shares at $21.17 each.</li><li>Private placement expected to raise about $100 million in gross proceeds.</li><li>Funds will support Phase 2 trial for LB-102 in major depressive disorder.</li><li>Participation includes established institutional investors like Balyasny Asset Management.</li><li>Closing expected by February 6, 2026, pending customary conditions.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Balyasny Asset Management (N/A)</strong>: Participated in the private placement, indicating institutional confidence.</li><li><strong>Caligan Partners (N/A)</strong>: Involved in the financing, highlighting interest from established investors.</li><li><strong>Piper Sandler (PIPR)</strong>: Acted as placement agent, reinforcing market credibility.</li><li><strong>Stifel (SF)</strong>: Assisted in placement, potentially impacting future deal-making.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The news falls under &#039;Corporate Developments&#039; as it directly pertains to LBRX&#039;s strategy to raise capital for clinical trials, a critical step for advancing product development and achieving market presence in competitive biopharmaceutical sectors.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Private placement could improve liquidity and fund critical trials for LBR-102.</li><li>Positive trial results could significantly increase stock valuation in near-term.</li><li>Institutional interest may drive stock price higher post-placement.</li><li>Delayed trial outcomes or news could negatively impact stock confidence.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Securities purchase agreement for 3,306,571 shares at $21.17 each.</li><li>Pre-funded warrants to purchase 1,417,107 shares priced at $21.1699.</li><li>Anticipated gross proceeds from the placement are $100 million.</li><li>Placement expected to close around February 6, 2026.</li><li>Lead product candidate LB-102 targets schizophrenia and major depressive disorder.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>LBRX is positioned for growth; buy ahead of the trial funding and expected developments.</p>
  </section>
</section>


<article>
    <h2>LB Pharmaceuticals Secures $100 Million in Private Placement</h2>
    <p>On February 5, 2026, <strong>LB Pharmaceuticals Inc</strong> (Nasdaq: <strong>LBRX</strong>), a late-stage biopharmaceutical company focused on developing innovative therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders, announced a significant financial milestone. The Company revealed a securities purchase agreement targeting a private placement that will generate approximately <strong>$100 million</strong> in gross proceeds before transaction-related expenses.</p>

    <section>
        <h3>Key Details of the Private Placement</h3>
        <p>LB Pharmaceuticals will sell <strong>3,306,571 shares</strong> of its common stock and <strong>pre-funded warrants</strong> to purchase up to <strong>1,417,107 shares</strong> to select institutional investors. The purchase price for each share of common stock is set at <strong>$21.17</strong>, while the pre-funded warrants are priced at <strong>$21.1699</strong>. This pricing reflects a minor adjustment from the price of the underlying common stock due to the $0.0001 exercise price of the warrants.</p>
        <p>The completion of this private placement is projected to occur on or about <strong>February 6, 2026</strong>, pending customary closing conditions.</p>
    </section>

    <section>
        <h3>Participating Investors and Advisors</h3>
        <p>Participation in this financing round includes both new and existing institutional investors such as:</p>
        <ul>
            <li>Balyasny Asset Management L.P.</li>
            <li>Caligan Partners</li>
            <li>Commodore Capital</li>
            <li>Deep Track Capital</li>
            <li>Nantahala Capital</li>
            <li>Pivotal bioVenture Partners</li>
            <li>Spruce Street Capital</li>
            <li>TCGX</li>
            <li>Trails Edge Capital Partners</li>
        </ul>
        <p>Leading financial firms <strong>Leerink Partners</strong>, <strong>Piper Sandler</strong>, and <strong>Stifel</strong> acted as placement agents for this transaction.</p>
    </section>

    <section>
        <h3>Intended Use of Proceeds</h3>
        <p>The net proceeds from this private placement are earmarked for several critical initiatives, including:</p>
        <ul>
            <li>Funding a Phase 2 trial of <strong>LB-102</strong> for treating major depressive disorder.</li>
            <li>Supporting general corporate purposes and working capital needs.</li>
        </ul>
    </section>

    <section>
        <h3>Regulatory Considerations</h3>
        <p>It is essential to note that the securities involved in this private placement have not been registered under the <em>Securities Act of 1933</em> or applicable state laws. Consequently, these securities cannot be offered or sold in the United States unless registered or an exemption applies.</p>
        <p>Along with the securities purchase agreement, a registration rights agreement has been executed, obligating LB Pharmaceuticals to file a registration statement with the <strong>Securities and Exchange Commission</strong> (SEC) to register the resale of the shares issued in the placement.</p>
    </section>

    <section>
        <h3>Company Overview</h3>
        <p>LB Pharmaceuticals is at the forefront of biopharmaceutical development, particularly in the late-stage trials for therapies aimed at neuropsychiatric conditions. The Company’s lead product candidate, <strong>LB-102</strong>, holds the potential to become the first benzamide antipsychotic approved for neuropsychiatric disorders within the United States.</p>
        <p>If successfully developed and approved, LB-102 may represent a breakthrough in psychiatric treatment options, offering a balanced clinical efficacy and tolerability profile, which may provide a viable alternative to existing therapies.</p>
    </section>

    <section>
        <h3>Forward-Looking Statements</h3>
        <p>LB Pharmaceuticals emphasizes the forward-looking nature of certain statements within this announcement, as defined by the <em>Private Securities Litigation Reform Act of 1995</em>. Terms like "anticipate," "expect," and "believe" indicate potential future outcomes that may differ materially due to various risks and uncertainties, including:</p>
        <ul>
            <li>The uncertainty of achieving future funding and commercialization of LB-102.</li>
            <li>Competition from other entities developing similar therapies.</li>
            <li>Regulatory approval challenges.</li>
        </ul>
    </section>

    <section>
        <h3>Contact Information</h3>
        <p>For additional information, media, and investor inquiries, please contact:</p>
        <p><strong>Ellen Rose</strong><br> Email: <a href="mailto:rose@lbpharma.us">rose@lbpharma.us</a></p>
    </section>
</article>

LB Pharmaceuticals (LBRX) plans to raise approximately $100 million through a private placement of shares to fund a Phase 2 trial for its lead candidate, LB-102. The anticipated proceeds may enhance the company's position in the neuropsychiatric market, leading to potential stock appreciation following the closure of the placement.

LB Pharmaceuticals Announces $100.0 Million Private Placement

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News